These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27622064)

  • 1. Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.
    Kearney CJ; Ramsbottom KM; Voskoboinik I; Darcy PK; Oliaro J
    Oncoimmunology; 2016 Aug; 5(8):e1196308. PubMed ID: 27622064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients.
    Sanchez-Correa B; Gayoso I; Bergua JM; Casado JG; Morgado S; Solana R; Tarazona R
    Immunol Cell Biol; 2012 Jan; 90(1):109-15. PubMed ID: 21383766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.
    Kaito Y; Sugimoto E; Nakamura F; Tsukune Y; Sasaki M; Yui S; Yamaguchi H; Goyama S; Nannya Y; Mitani K; Tamura H; Imai Y
    Haematologica; 2024 Apr; 109(4):1107-1120. PubMed ID: 37731380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the TIGIT-CD155/CD112 axis enhances functionality of NK-92 but not cytokine-induced memory-like NK cells toward CD155-expressing acute myeloid leukemia.
    Seel K; Schirrmann RL; Stowitschek D; Ioseliani T; Roiter L; Knierim A; André MC
    Cancer Immunol Immunother; 2024 Jul; 73(9):180. PubMed ID: 38967649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD155 and CD112 as possible therapeutic targets of
    Kaito Y; Hirano M; Futami M; Nojima M; Tamura H; Tojo A; Imai Y
    Oncol Lett; 2022 Feb; 23(2):51. PubMed ID: 34992684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
    Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma.
    Cho MM; Song L; Quamine AE; Szewc F; Shi L; Ebben JD; Turicek DP; Kline JM; Burpee DM; Lafeber EO; Phillips MF; Ceas AS; Erbe AK; Capitini CM
    bioRxiv; 2024 Jun; ():. PubMed ID: 37333207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased CD112 expression in methylcholanthrene-induced tumors in CD155-deficient mice.
    Nagumo Y; Iguchi-Manaka A; Yamashita-Kanemaru Y; Abe F; Bernhardt G; Shibuya A; Shibuya K
    PLoS One; 2014; 9(11):e112415. PubMed ID: 25384044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
    El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
    Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.
    Mastaglio S; Wong E; Perera T; Ripley J; Blombery P; Smyth MJ; Koldej R; Ritchie D
    Blood Adv; 2018 Feb; 2(4):335-346. PubMed ID: 29449224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T Cell Subsets in Patients with Acute Myeloid Leukemia.
    Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Sanchez-Correa B; Guerrero B; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Sanchez-Garcia J; Serrano J; Martin C; Duran E; Alonso C; Solana R; Tarazona R
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32764229
    [No Abstract]   [Full Text] [Related]  

  • 12. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases.
    Chan CJ; Andrews DM; McLaughlin NM; Yagita H; Gilfillan S; Colonna M; Smyth MJ
    J Immunol; 2010 Jan; 184(2):902-11. PubMed ID: 20008292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse.
    Khaznadar Z; Henry G; Setterblad N; Agaugue S; Raffoux E; Boissel N; Dombret H; Toubert A; Dulphy N
    Eur J Immunol; 2014 Oct; 44(10):3068-80. PubMed ID: 25041786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells.
    Mensurado S; Condeço C; Sánchez-Martínez D; Shirley S; Coelho RML; Tirado N; Vinyoles M; Blanco-Domínguez R; Barros L; Galvão B; Custódio N; Gomes da Silva M; Menéndez P; Silva-Santos B
    Blood; 2024 Apr; 143(15):1488-1495. PubMed ID: 38437507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).
    Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A
    Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes with NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells.
    Davis ZB; Sowrirajan B; Cogswell A; Ward JP; Planelles V; Barker E
    AIDS Res Hum Retroviruses; 2017 Feb; 33(2):93-100. PubMed ID: 27296670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis.
    Chashchina A; Märklin M; Hinterleitner C; Salih HR; Heitmann JS; Klimovich B
    Sci Rep; 2021 Sep; 11(1):18012. PubMed ID: 34504191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of T Cell Costimulation via DNAM-1 in Kidney Transplantation.
    Kraus AK; Chen J; Edenhofer I; Ravens I; Gaspert A; Cippà PE; Mueller S; Wuthrich RP; Segerer S; Bernhardt G; Fehr T
    PLoS One; 2016; 11(2):e0147951. PubMed ID: 26840537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.
    Bottino C; Castriconi R; Pende D; Rivera P; Nanni M; Carnemolla B; Cantoni C; Grassi J; Marcenaro S; Reymond N; Vitale M; Moretta L; Lopez M; Moretta A
    J Exp Med; 2003 Aug; 198(4):557-67. PubMed ID: 12913096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
    Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
    Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.